TAVR (Transcatheter Aortic Valve Replacement) in India and UAE | Complete Patient Guide

• ELIGIBILITY — CLINICAL INDICATIONS:

• Symptomatic severe aortic stenosis: aortic valve area (AVA) ≤1.0 cm² (indexed AVA ≤0.6 cm²/m²), mean gradient ≥40 mmHg, or peak jet velocity ≥4 m/s

• High or prohibitive surgical risk: STS-PROM score ≥8% or EuroSCORE II ≥6%, or presence of risk factors not captured by scores (porcelain aorta, chest radiation sequelae, hostile mediastinum, severe frailty)

• Intermediate surgical risk: STS-PROM 4–8% — Heart Team decision with shared patient preference

• Low surgical risk (STS-PROM <4%): increasingly offered TAVR per PARTNER 3 / Evolut Low Risk data, especially patients ≥65 years

• Bicuspid aortic valve stenosis: feasible at expert centers with MDCT-guided planning, though considered off-label in some jurisdictions

• Failed surgical bioprosthesis requiring redo intervention (Valve-in-Valve TAVR): well-validated with favorable registry outcomes

• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:

• Transthoracic Echocardiography (TTE) + Transesophageal Echocardiography (TEE): valve morphology, gradient quantification, LV function (EF), mitral/tricuspid co-pathology

• Cardiac CT Angiography (CCTA / MDCT): annular sizing (perimeter- and area-derived), calcium scoring (LVOT, leaflet, sub-annular), access route assessment (iliofemoral diameters, tortuosity, calcification), coronary ostial heights

• Coronary Angiography / CT Coronary Angiography: assessment of obstructive CAD requiring concurrent PCI

• 6-Minute Walk Test (6MWT) + Katz Index of Independence: functional and frailty assessment

• Carotid Duplex Ultrasound: cerebrovascular risk stratification

• Complete Blood Count, BMP, Coagulation Panel (PT/INR, aPTT), HbA1c, eGFR/Creatinine: procedural risk and contrast safety

• Chest X-Ray + Pulmonary Function Tests (if COPD suspected)

• RELATIVE CONTRAINDICATIONS / EXCLUSION CRITERIA:

• Severe anatomical unsuitability: insufficient annular diameter (<18 mm or >30 mm for available devices), extremely hostile iliofemoral access without feasible alternative access

• Severe concomitant valvular disease requiring simultaneous surgical correction (e.g., severe MR with structural etiology)

• Life expectancy <12 months from non-cardiac comorbidities

• Active endocarditis or bacteremia

• Untreated significant coronary artery disease with ongoing ischemia (must be revascularized before or at time of TAVR)

• Hypersensitivity to contrast agents not manageable with premedication

• Intracardiac thrombus

TAVR technology has evolved through four generations, and the choice of device and access strategy is individualized by the Heart Team based on MDCT annular measurements, calcium distribution, coronary anatomy, and patient vascular access.

ACCESS ROUTES:

• Transfemoral (TF) Access [Preferred — >90% of cases]: A 14–18 French delivery sheath is introduced percutaneously via the common femoral artery under ultrasound guidance. Completely percutaneous closure using two pre-deployed ProGlide or MANTA vascular closure devices has eliminated the need for surgical cutdown in most patients. TF-TAVR is associated with the shortest procedure times, lowest bleeding rates, and fastest recovery — it is the default route when iliofemoral diameters exceed 5.5 mm and calcification is acceptable.

• Transaxillary / Subclavian Access: Used when femoral access is prohibitive; the delivery system is introduced via the axillary or subclavian artery. Requires careful assessment of vessel diameter (≥6 mm) and proximity to internal mammary grafts in post-CABG patients.

• Transcaval Access: A novel approach where the delivery system crosses from the inferior vena cava to the aorta via an electrosurgical puncture, sealed post-deployment with a nitinol plug; used at experienced centers when all arterial routes are unfeasible.

• Transapical (TA) / Transaortic (TAo) Access: Surgical approaches requiring a mini-thoracotomy or mini-sternotomy; reserved for patients with no suitable vascular access and performed by hybrid cardiac surgery teams. Associated with higher morbidity than TF access.

VALVE TECHNOLOGIES:

• Balloon-Expandable Valves — Edwards SAPIEN 3 / SAPIEN 3 Ultra RESILIA: Deployed by rapid pacing and balloon inflation; pericardial leaflets on a cobalt-chromium frame. Available in sizes 20–29 mm. Ultra RESILIA platform uses anti-calcification treated bovine pericardium for improved long-term durability. Excellent paravalvular leak (PVL) sealing via an outer skirt.

• Self-Expanding Valves — Medtronic Evolut PRO+ / FX: A supra-annular, intra-annular nitinol frame with porcine pericardial leaflets. Repositionable and fully retrievable before release. Supra-annular design yields larger effective orifice area (EOA), favoring patients with small annuli. Evolut FX features enhanced deliverability and a dual-layer outer skirt.

• Self-Expanding Valves — Boston Scientific Acurate neo2: A top-down self-expanding system with a unique stabilization arch and upper crown; favors rapid, controlled deployment without rapid pacing.

• Mechanically Expanded — GATE (Anteris) and next-generation platforms: Emerging technologies offering operator-controlled, non-balloon, non-self-expanding deployment mechanics for enhanced precision.

ADVANCED TECHNIQUES:

• Valve-in-Valve (ViV) TAVR: Transcatheter valve implanted within a failed surgical bioprosthesis. Requires precise MDCT planning for virtual TAVR simulation, coronary occlusion risk assessment, and consideration of BASILICA (Bioprosthetic or Native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction) if coronary risk is elevated.

• BASILICA Procedure: Electrosurgical leaflet laceration performed immediately before TAVR to prevent coronary obstruction in high-risk anatomies (low coronary ostia, large/bulky native leaflets, Valve-in-Valve scenarios).

• LAAO + TAVR (Combined Procedures): Simultaneous Left Atrial Appendage Occlusion (e.g., Watchman FLX) and TAVR in a single session for patients with concurrent AF and high bleeding risk, eliminating long-term anticoagulation.

• Cerebral Embolic Protection (CEP): Devices such as the Sentinel Cerebral Protection System (Boston Scientific) — a dual-filter system deployed in the brachiocephalic and left common carotid arteries — capture embolic debris during TAVR, reducing subclinical stroke risk. Recommended at high-volume centers for patients with elevated cerebrovascular risk.

• Minimalist TAVR Protocol: Fully percutaneous TF-TAVR under local anesthesia with conscious sedation (no general anesthesia), guided by fluoroscopy ± intracardiac echocardiography (ICE) rather than TEE, enabling same-day or next-day discharge in select low-risk patients.

SURGICAL AORTIC VALVE REPLACEMENT (SAVR) — COMPARISON CONTEXT:

Conventional SAVR via median sternotomy with cardiopulmonary bypass remains the gold standard for young low-risk patients (<65 years) who may benefit from mechanical valve longevity and in whom TAVR valve durability data beyond 10 years remains limited. Minimally Invasive SAVR (mini-sternotomy or right anterior mini-thoracotomy) reduces blood loss and recovery time but still requires cardioplegic arrest. The Heart Team weighs TAVR vs. SAVR considering age, anatomy, frailty, valve durability expectations, and patient preference.

PHASE 1 — REMOTE CONSULTATION & CASE REVIEW (Weeks 1–2 before travel):

• Patient submits medical records (echocardiography reports, CT scans, coronary angiography, clinical notes) to GAF Healthcare's medical concierge team.

• Records are reviewed by a senior interventional cardiologist at the chosen partner center within 48–72 hours.

• A structured teleconsultation is arranged: Heart Team preliminary opinion, provisional device selection, access route suitability, and cost estimate provided.

• GAF Healthcare initiates e-Medical Visa application (India) or entry visa facilitation (UAE) and coordinates travel logistics.

PHASE 2 — ARRIVAL & PRE-PROCEDURAL WORKUP (Days 1–3 in country):

• Day 1: Airport reception by GAF Healthcare's dedicated coordinator; transfer to hospital or partner accommodation.

• Day 2: Outpatient or inpatient workup — MDCT annular sizing (gold standard: 0.5 mm slice thickness cardiac CT with retrospective gating), repeat TTE/TEE, coronary angiography (if not recently performed), 6MWT, frailty assessment, anesthesia consultation, full laboratory panel.

• Day 3: Formal Heart Team conference — final decision on device choice (e.g., SAPIEN 3 Ultra 26 mm vs. Evolut PRO+ 29 mm), access route (transfemoral vs. alternative), anesthesia strategy (conscious sedation vs. general anesthesia), CEP device use, and anticoagulation plan. Patient consenting and pre-procedure hydration protocol initiated.

PHASE 3 — THE TAVR PROCEDURE (Day 4):

• Patient transferred to hybrid catheterization laboratory / hybrid OR — a specialized suite integrating high-resolution fluoroscopy (e.g., Siemens ARTIS icono, Philips Azurion), TEE or ICE imaging, hemodynamic monitoring, and full cardiac surgical backup.

• Vascular access established under ultrasound guidance; two vascular closure devices pre-deployed (Perclose ProGlide technique or MANTA device).

• Diagnostic aortography performed to confirm annular orientation and coronary ostial heights.

• Transcatheter valve crimped and loaded onto delivery catheter; advanced across the aortic arch under continuous fluoroscopic guidance.

• For balloon-expandable systems: atrioventricular pacing at 180–200 bpm induces transient cardiac standstill for valve deployment during balloon inflation (≈5 seconds).

• For self-expanding systems: controlled, repositionable deployment without rapid pacing, confirmed by angiography and echocardiography.

• Post-deployment aortography and TEE/ICE: assessment of valve position, paravalvular leak (PVL) grade, coronary flow patency, and new conduction disturbances (LBBB, AV block).

• Procedure duration: 60–120 minutes for uncomplicated transfemoral TAVR.

• Access sites closed percutaneously; patient transferred to cardiac ICU.

PHASE 4 — POST-PROCEDURAL ICU & STEP-DOWN (Days 4–7):

• ICU monitoring (12–24 hours): continuous cardiac telemetry for new-onset AV block or pacemaker dependency (occurs in ~10–15% with self-expanding valves, ~5–8% with balloon-expandable valves); hemodynamic stability; renal function (contrast nephropathy surveillance); vascular access site assessment.

• Echocardiography on Day 1 post-procedure: confirms valve position, gradient reduction, and PVL assessment.

• Ambulation initiated within 24 hours if transfemoral access is used and hemodynamics are stable.

• Antiplatelet therapy initiated: dual antiplatelet (aspirin 75–100 mg + clopidogrel 75 mg) for 3–6 months per POPular-TAVI evidence, transitioning to aspirin monotherapy thereafter. Patients with AF receive anticoagulation (NOAC preferred) per ENVISAGE-TAVI AF trial data.

• Pacemaker implantation if high-degree AV block or complete heart block develops; rhythm monitoring typically extended 48–72 hours before discharge.

• Discharge criteria: hemodynamically stable, ambulating independently, no significant PVL, no arrhythmia requiring intervention, echocardiographic confirmation of prosthesis function.

PHASE 5 — EARLY RECOVERY IN-COUNTRY (Weeks 1–4 after procedure):

• Week 1–2: Light activity only; daily wound site inspection; avoid driving. Outpatient cardiology review at Day 7–10 with repeat TTE and 12-lead ECG.

• Week 2–3: Graduated activity; 10–15 minute walks twice daily; no heavy lifting (>5 kg). Blood pressure and renal function monitoring.

• Week 3–4: Cardiac rehabilitation assessment; dietary sodium restriction reinforced; medication reconciliation.

• FIT-TO-FLY ASSESSMENT: Patients are cleared for short-haul flights (≤4 hours) typically at 3 weeks and long-haul intercontinental flights at 6–8 weeks, subject to: stable hemodynamics, no active arrhythmia, no pacemaker lead maturation concerns, wound healing, and physician sign-off. GAF Healthcare provides a medical fitness-to-fly certificate.

PHASE 6 — LONG-TERM FOLLOW-UP (Months 1–12+):

• One-month follow-up: TTE, clinical review, antiplatelet/anticoagulation reassessment.

• Six-month follow-up: TTE, 6MWT, symptom assessment.

• Annual follow-up: TTE every year for prosthesis durability monitoring (leaflet thickening, structural valve deterioration assessment with 4D CT at 5 years). Subclinical leaflet thrombosis (HALT) surveillance per evolving guidelines.

• GAF Healthcare provides a comprehensive digital medical summary for the patient's home cardiologist to ensure seamless continuity of care.